이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dimed Distribuidora de Medicamentos 미래 성장

Future 기준 확인 4/6

Dimed Distribuidora de Medicamentos은 연간 수입과 매출이 각각 20.4%와 11.3% 증가할 것으로 예상되고 EPS는 연간 38.5%만큼 증가할 것으로 예상됩니다.

주요 정보

22.8%

수익 성장률

38.5%

EPS 성장률

Consumer Retailing 수익 성장	31.8%
매출 성장률	11.4%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	27 Jun 2024

최근 미래 성장 업데이트

Recent updates

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15

수익 및 매출 성장 예측

BOVESPA:PNVL3 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (BRL Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	6,478	258	N/A	N/A	3
12/31/2025	5,753	203	N/A	401	3
12/31/2024	5,065	159	N/A	347	2
3/31/2024	4,660	108	178	313	N/A
12/31/2023	4,461	93	157	297	N/A
9/30/2023	4,325	88	144	282	N/A
6/30/2023	4,211	83	175	325	N/A
3/31/2023	4,116	84	69	228	N/A
12/31/2022	3,990	86	24	205	N/A
9/30/2022	3,799	85	17	198	N/A
6/30/2022	3,584	83	21	189	N/A
3/31/2022	3,375	80	15	175	N/A
12/31/2021	3,225	79	-4	131	N/A
9/30/2021	3,135	79	-56	78	N/A
6/30/2021	3,032	79	-58	63	N/A
3/31/2021	2,878	62	-41	57	N/A
12/31/2020	2,819	56	46	131	N/A
9/30/2020	2,764	56	82	147	N/A
6/30/2020	2,754	62	34	90	N/A
3/31/2020	2,780	78	73	133	N/A
12/31/2019	2,725	77	75	129	N/A
9/30/2019	2,638	80	89	131	N/A
6/30/2019	2,562	79	65	106	N/A
3/31/2019	2,500	76	72	117	N/A
12/31/2018	2,432	75	51	110	N/A
9/30/2018	2,359	65	-20	45	N/A
6/30/2018	2,317	59	-1	62	N/A
3/31/2018	2,282	59	-27	29	N/A
12/31/2017	2,258	60	N/A	41	N/A
9/30/2017	2,238	60	N/A	78	N/A
6/30/2017	2,191	59	N/A	68	N/A
3/31/2017	2,146	57	N/A	104	N/A
12/31/2016	2,129	53	N/A	102	N/A
9/30/2016	2,095	53	N/A	92	N/A
6/30/2016	2,074	50	N/A	93	N/A
3/31/2016	2,043	50	N/A	76	N/A
12/31/2015	1,986	45	N/A	73	N/A
9/30/2015	1,963	44	N/A	59	N/A
6/30/2015	1,927	43	N/A	56	N/A
3/31/2015	1,916	48	N/A	26	N/A
12/31/2014	1,887	49	N/A	23	N/A
9/30/2014	1,835	50	N/A	29	N/A
6/30/2014	1,823	58	N/A	50	N/A
3/31/2014	1,786	55	N/A	66	N/A
12/31/2013	1,740	56	N/A	62	N/A
9/30/2013	1,687	54	N/A	46	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PNVL3 의 연간 예상 수익 증가율( 20.4% )이 saving rate( 9.9% 보다 높습니다. ).

수익 vs 시장: PNVL3 의 연간 수익( 20.4% ) BR 시장( 14.1% 보다 빠르게 성장할 것으로 예상됩니다. 14.1% 연간).

고성장 수익: PNVL3 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: PNVL3 의 수익(연간 11.3% ) BR 시장( 7.2% 보다 빠르게 성장할 것으로 예상됩니다. 7.2% 연간).

고성장 수익: PNVL3 의 수익(연간 11.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PNVL3 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Dimed Distribuidora de Medicamentos 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 8.5% to R$16.13

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Price target decreased to R$22.85

Price target decreased to R$30.20

Recent updates

Price target decreased by 8.5% to R$16.13

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.12 in 1Q 2023)

Full year 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of R$0.068 per share at 1.9% yield

Third quarter 2023 earnings released: EPS: R$0.16 (vs R$0.12 in 3Q 2022)

Upcoming dividend of R$0.046 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: R$0.15 (vs R$0.16 in 2Q 2022)

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Full year 2022 earnings released: EPS: R$0.58 (vs R$0.53 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Second quarter 2022 earnings released

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

First quarter 2022 earnings: Revenues exceed analyst expectations

Price target decreased to R$22.85

No independent directors

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Full year 2021 earnings: EPS misses analyst expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorated over the past week

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Price target decreased to R$30.20

Third quarter 2021 earnings released

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorated over the past week

Upcoming dividend of R$0.034 per share

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Dimed S.A. Distribuidora de Medicamentos(BOVESPA:PNVL4) dropped from Brazil Special Tag Along Stock Index

Dimed S.A. Distribuidora de Medicamentos announced that it expects to receive funding from Kinea Private Equity Investimentos S.A.

Dimed S.A. Distribuidora de Medicamentos has completed a Follow-on Equity Offering in the amount of BRL 1.036713 billion.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견